Lung Cancer

Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses advancements in the management of immune-related adverse events (irAEs) in patients with lung cancer during the 5th Annual Miami Lung Cancer Conference.

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses pembrolizumab (Keytruda) in the first-line treatment of non–small cell lung cancer during the 5th Annual Miami Lung Cancer Conference.

Immune-based therapies continue to show promising signals for patients with small cell lung cancer and mesothelioma, but better predictive biomarkers are needed to determine who is most likely to benefit.

With durvalumab (Imfinzi) being hailed as a potentially practice changing therapy in locally advanced non–small cell lung cancer, ongoing studies are seeking to determine the efficacy of immunotherapy in earlier stages of disease.

Thomas E. Stinchcombe, MD, professor of medicine, Duke Cancer Institute, discusses pivotal trials that have reshaped the standard of care in non–small cell lung cancer (NSCLC).

Jason M. Long, MD, assistant professor of surgery, Division of Cardiothoracic Surgery, University of North Carolina at Chapel Hill, discusses specific minimally invasive thoracic surgery approaches in lung cancer.

David C. Portnoy, MD, discusses emerging developments with targeted agents in lung cancer.

Jared Weiss, MD, associate professor, School of Medicine, UNC Chapel Hill, UNC Lineberger Comprehensive Cancer Center, discusses the clinical applications of the phase III PACIFIC trial in non–small cell lung cancer in the United States.

Lee S. Schwartzberg, MD, FACP, chief and professor, Division of Hematology/Oncology, the University of Tennessee Health Science Center, medical director, West Clinic, executive director, West Cancer Center, discusses several emerging biomarkers in non–small cell lung cancer (NSCLC).

Gilberto Lopes, MD, discusses the global disparities occurring in lung cancer care and some of the steps that are being taken to better serve patients with the available and emerging therapeutic approaches.

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the rationale behind the design of PACIFIC, a trial that investigated the use of durvalumab (Imfinzi) in patients with locally advanced, unresectable stage III lung cancer.

Julie R. Brahmer, MD, discusses first-line immunotherapy, targeted therapies for molecularly driven tumors, and recently released guidelines for the treatment of patients with lung cancer.

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses testing for and treating resistance to EGFR tyrosine kinase inhibitor (TKI) therapy in non–small cell lung cancer.

Sarah B. Goldberg, MD, discusses testing for and treating resistance to EGFR TKI therapy in non-small cell lung cancer.

Lee Schwartzberg, MD, discusses the importance of next-generation sequencing and the state of biomarker development in the management of patients with NSCLC.

The FDA has approved a supplemental biologics license application adding a 4-week dosing schedule for nivolumab across several of the PD-1 inhibitor’s indications.

David R. Spigel, MD, discusses the status of immunotherapy in locally advanced NSCLC and highlights recent milestones.

Benjamin P. Levy, MD, highlights trials that continue to shape the treatment landscape for patients with lung cancer.

Shirley Michelle Shiller, DO, discusses the application of biomarkers and the importance of educating practitioners on treatment advancements in NSCLC.

Claude Denham, MD, discusses the challenges with immunotherapy in NSCLC cancer, as well as the promise of combination therapy.